GlobeNewswire Clinical StudiesOriginal article
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
ConferenceMIPLYFFA®Positive
AI Analysis
Summary
Zevra Therapeutics will present long-term real-world data on MIPLYFFA® for Niemann-Pick Disease Type C at the 2026 SSIEM Annual Symposium, highlighting sustained disease stabilization and consistent safety across diverse patient populations from U.S. and German early access programs.
Outcome Details
Presentation of long-term real-world data from U.S. and German early access programs showing sustained disease stabilization and consistent safety profile
Importance:5/10
Sentiment:
0.60
MIPLYFFANiemann-Pick Disease Type Creal-world dataearly access programSSIEMconference presentation
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 25, 2026 11:30 AM